Rechercher | LIFE-ND Graduate Community

Ajouter une nouvelle offre d'emploi Health

2026-06-26 09:19:21 -

The Cosentyx Drug Market was valued at $2.1 billion in 2024 and is projected to reach $4.5 billion by 2035, growing at a CAGR of 7.1%. Cosentyx (secukinumab), developed by Novartis, is a human monoclonal antibody that selectively binds to interleukin-17A (IL-17A), a key cytokine involved in inflammatory diseases. The market is primarily driven by the rising prevalence of autoimmune conditions...

0 Commentaires 0 Parts 83 Vue 0 Aperçu